JP2017533952A - シクロピロクス、シクロピロクスオラミン又はシクロピロクスプロドラッグを用いる、膀胱癌の処置方法 - Google Patents
シクロピロクス、シクロピロクスオラミン又はシクロピロクスプロドラッグを用いる、膀胱癌の処置方法 Download PDFInfo
- Publication number
- JP2017533952A JP2017533952A JP2017526594A JP2017526594A JP2017533952A JP 2017533952 A JP2017533952 A JP 2017533952A JP 2017526594 A JP2017526594 A JP 2017526594A JP 2017526594 A JP2017526594 A JP 2017526594A JP 2017533952 A JP2017533952 A JP 2017533952A
- Authority
- JP
- Japan
- Prior art keywords
- ciclopirox
- cpx
- aliphatic
- bladder cancer
- pom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C**(C)C*(C)ON(C(C1CCCCC1)=CC(*)=C1)C1=O Chemical compound C**(C)C*(C)ON(C(C1CCCCC1)=CC(*)=C1)C1=O 0.000 description 4
- JKJUSISTYXRUFK-UHFFFAOYSA-N CC(CC(C)ON(C(C1CCCCC1)=CC(C)=C1)C1=O)OC Chemical compound CC(CC(C)ON(C(C1CCCCC1)=CC(C)=C1)C1=O)OC JKJUSISTYXRUFK-UHFFFAOYSA-N 0.000 description 1
- DSEKFIKYEYOMDV-UHFFFAOYSA-N CCCON(C(C1CCCCC1)=CC(C)=C1)C1=O Chemical compound CCCON(C(C1CCCCC1)=CC(C)=C1)C1=O DSEKFIKYEYOMDV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078069P | 2014-11-11 | 2014-11-11 | |
| US62/078,069 | 2014-11-11 | ||
| US201562134747P | 2015-03-18 | 2015-03-18 | |
| US62/134,747 | 2015-03-18 | ||
| PCT/US2015/059955 WO2016077346A1 (en) | 2014-11-11 | 2015-11-10 | Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017533952A true JP2017533952A (ja) | 2017-11-16 |
| JP2017533952A5 JP2017533952A5 (enExample) | 2018-12-20 |
Family
ID=55954945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526594A Pending JP2017533952A (ja) | 2014-11-11 | 2015-11-10 | シクロピロクス、シクロピロクスオラミン又はシクロピロクスプロドラッグを用いる、膀胱癌の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170304329A1 (enExample) |
| EP (1) | EP3217980B1 (enExample) |
| JP (1) | JP2017533952A (enExample) |
| CN (2) | CN116687941A (enExample) |
| DK (1) | DK3217980T3 (enExample) |
| ES (1) | ES2836208T3 (enExample) |
| HR (1) | HRP20201893T1 (enExample) |
| HU (1) | HUE052670T2 (enExample) |
| PL (1) | PL3217980T3 (enExample) |
| PT (1) | PT3217980T (enExample) |
| RS (1) | RS61222B1 (enExample) |
| WO (1) | WO2016077346A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11753379B2 (en) | 2018-05-30 | 2023-09-12 | Clariant International Ltd | Process for forming 2-hydroxypyridine-1-oxide or derivatives thereof |
| CN113194945B (zh) * | 2018-08-23 | 2024-07-23 | 佩勒梅德有限公司 | 环吡酮的抑制hbv核心组装的用途 |
| WO2021078937A1 (en) * | 2019-10-25 | 2021-04-29 | Deutsches Krebsforschungszentrum | Treatment of stat3 related diseases by iron chelators |
| EP4193989A1 (en) | 2021-12-09 | 2023-06-14 | Atlas Molecular Pharma, S.L. | A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004007676A2 (en) * | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
| JP2013528619A (ja) * | 2010-06-01 | 2013-07-11 | ビオトヘルイク， インコーポレイテッド | ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用 |
| JP2013544289A (ja) * | 2010-12-02 | 2013-12-12 | カンザス大学 | ６−シクロヘキシル−１−ヒドロキシ−４−メチルピリジン−２（１ｈ）−オンのプロドラッグおよびその誘導体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU754965B2 (en) | 1997-12-31 | 2002-11-28 | University Of Kansas, The | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| WO2010048712A1 (en) | 2008-10-31 | 2010-05-06 | University Health Network | Ciclopirox and cytarabine for the treatment of leukemic disorders |
-
2015
- 2015-11-10 DK DK15859268.3T patent/DK3217980T3/da active
- 2015-11-10 PT PT158592683T patent/PT3217980T/pt unknown
- 2015-11-10 RS RS20201438A patent/RS61222B1/sr unknown
- 2015-11-10 HU HUE15859268A patent/HUE052670T2/hu unknown
- 2015-11-10 WO PCT/US2015/059955 patent/WO2016077346A1/en not_active Ceased
- 2015-11-10 ES ES15859268T patent/ES2836208T3/es active Active
- 2015-11-10 CN CN202310102470.8A patent/CN116687941A/zh active Pending
- 2015-11-10 HR HRP20201893TT patent/HRP20201893T1/hr unknown
- 2015-11-10 JP JP2017526594A patent/JP2017533952A/ja active Pending
- 2015-11-10 EP EP15859268.3A patent/EP3217980B1/en active Active
- 2015-11-10 CN CN201580061284.8A patent/CN107206012A/zh active Pending
- 2015-11-10 PL PL15859268.3T patent/PL3217980T3/pl unknown
- 2015-11-10 US US15/526,164 patent/US20170304329A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004007676A2 (en) * | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
| JP2013528619A (ja) * | 2010-06-01 | 2013-07-11 | ビオトヘルイク， インコーポレイテッド | ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用 |
| JP2013544289A (ja) * | 2010-12-02 | 2013-12-12 | カンザス大学 | ６−シクロヘキシル−１−ヒドロキシ−４−メチルピリジン−２（１ｈ）−オンのプロドラッグおよびその誘導体 |
Non-Patent Citations (1)
| Title |
|---|
| INT J CANCER, 2010, VOL.127(10), P.2467-2477, JPN6019040581, ISSN: 0004137882 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DK3217980T3 (da) | 2020-12-07 |
| EP3217980A4 (en) | 2018-05-02 |
| RS61222B1 (sr) | 2021-01-29 |
| HRP20201893T1 (hr) | 2021-02-05 |
| ES2836208T3 (es) | 2021-06-24 |
| HUE052670T2 (hu) | 2021-05-28 |
| US20170304329A1 (en) | 2017-10-26 |
| WO2016077346A1 (en) | 2016-05-19 |
| CN107206012A (zh) | 2017-09-26 |
| CN116687941A (zh) | 2023-09-05 |
| EP3217980B1 (en) | 2020-10-14 |
| PL3217980T3 (pl) | 2021-03-22 |
| EP3217980A1 (en) | 2017-09-20 |
| PT3217980T (pt) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11485726B2 (en) | Compound for inhibiting and degrading tyrosine protein kinase ALK | |
| CN108379591B (zh) | 免疫激动剂靶向化合物的合成及其应用 | |
| JP6193268B2 (ja) | Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 | |
| US9545413B2 (en) | Methods of forming ciclopirox or derivatives thereof in a subject by administration of prodrug | |
| US10450305B2 (en) | LKB1-AMPK activators for therapeutic use in polycystic kidney disease | |
| EA023804B1 (ru) | Оксабициклогептаны, их получение и применение | |
| CN113143965B (zh) | 一种抑制肿瘤增殖的氨基富勒烯材料 | |
| CN101528754A (zh) | 使用结合wrn的分子的治疗方法 | |
| US20200123165A1 (en) | Kinase inhibitors | |
| US20200102264A1 (en) | Marmelin analogs and methods of use in cancer treatment | |
| EP3217980B1 (en) | Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer | |
| AU2017258304A1 (en) | 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/Cdc42 GTPases | |
| US20230312531A1 (en) | Prodigiosin Analogs And Methods Of Use | |
| CN120381528A (zh) | 用于治疗和预防纤维化疾病状态和癌症的化合物和方法 | |
| CN106995368B (zh) | 一种非atp竞争性fgfr1抑制剂及其应用 | |
| US12435091B2 (en) | RNA-binding protein multimerization inhibitors and methods of use thereof | |
| CN102532192B (zh) | 一种对乙酰氨基酚—磷酰氮芥抗肿瘤药物及其制备方法 | |
| CN118043053A (zh) | 治疗癌症的方法 | |
| WO2022118966A1 (ja) | 細胞内への核酸分子取り込み促進剤、医薬組成物、及び新規化合物 | |
| US20250228950A1 (en) | Prodrugs Activated by Reduction in the Cytosol | |
| WO2025194120A1 (en) | Zwitterionic polymer functionalized lipid nanoparticles for delivery of nucleic acids | |
| HK1254606B (en) | Chiral diaryl macrocycles and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181109 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191029 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200128 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200623 |